The Management of Amyotrophic Lateral Sclerosis (ALS): A Guide to Enhance Outcomes for Managed Care and Payer Professionals
Jointly provided by
Medical Education Resources   

This activity is supported by independent educational grants from Mitsubishi Tanabe Pharma America, Inc. and Amylyx.
You Are Invited to a CME/CE Live Webcast
2 Chances to Attend!

DayTimeRegister
Friday, May 13, 2022 11:30am-1:00pm ETWebcast Complete!
Wednesday, May 25, 2022 12:30pm-2:00pm ET Click here to reserve your spot

LEARN ABOUT
  • The burdens of ALS in terms of health care resource utilization, indirect costs, and member quality of life
  • Medical and pharmacy benefit design strategies that improve access to therapy and manage costs
  • Effective coordinated care interventions in the management of ALS
EXPERT FACULTY PRESENTERS
Terry D. Heiman-Patterson, MD
Professor of Neurology
Lewis Katz School of Medicine at Temple University
Director
Temple MDA/ALS Center of Hope
James T. Kenney, RPh, MBA
Founder and President
JT Kenney, LLC
Michael Kobernick, MD, MS, MS-PopH, CPE
Senior Medical Director – Health Plan Business
Blue Cross Blue Shield of Michigan
Lecturer
Jefferson College of Population Health
TARGET AUDIENCE
  • This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, and other managed health care professionals.
PROGRAM OVERVIEW

Amyotrophic lateral sclerosis (ALS) is characterized by a devastating disease course with significant clinical, economic, and humanistic burden. These disease-related challenges associated with ALS are compounded for managed care and other payer professionals who are tasked with managing rising health care expenditures and the specialty drug trend, as well as affiliated case managers who act as a conduit through which patients access specific components of care. The expert faculty will present and discuss recent insights into the management of patients who may benefit from effective therapeutic intervention for ALS via case-based discussions. In addition, the faculty panel, including managed care experts, will review important, relevant therapeutic category information.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to demonstrate improved ability to:
  • Characterize the clinical, economic, and humanistic burden of ALS in terms of health care resource utilization, indirect costs, and member quality of life
  • Outline the interdisciplinary components of effective coordinated care interventions in the management of ALS
  • Assess the value of appropriate, evidence-based drug therapy for slowing disease progression and minimizing direct expenditures in other categories
  • Characterize the adverse effect of excess cost-sharing and prohibitive coverage criteria on patient access and adherence
  • Implement medical and pharmacy benefit design strategies that improve access to therapy and manage costs with evidence-based clinical care for ALS
AGENDA
Pre-Activity Learning Assessment and Opening Comments/Overview
James T. Kenney, RPh, MBA
Integrating Evidence-Based ALS Treatment Options into Plan Algorithms
Terry Heiman-Patterson, MD
Appropriate Access to Pharmacotherapy for Slowing Disease Progression
James T. Kenney, RPh, MBA
Coordinating Interdisciplinary Management Interventions: ALS Case Scenarios
Michael Kobernick, MD, MS, MS-PopH, CPE
Audience Q&A Session
Key Takeaways and Closing Comments; Post-Activity Assessment and Evaluation
ACCREDITATION INFORMATION

Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources, Inc. (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This CE activity provides 1.5 contact hours of continuing nursing education.
Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 1.5 contact hours.

Pharmacy Credit
Medical Education Resources, Inc. (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA0003680-9999-22-010-L01-P
This activity is certified as knowledge-based CPE.

Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources, Inc. to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

If you have any questions, please call (215) 619-8812 or email info@impactedu.net.